Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses

Moxifloxacin and levofloxacin are currently recommended as empirical initial treatment options for community-acquired pneumonia (CAP) in China by clinical guidelines and widely used in clinical settings. Several clinical outcomes comparing the efficacy and safety profiles of moxifloxacin versus levo...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xiwen, Han, Yi, Jian, Yifei, Chen, Liping, Xuan, Jianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Data Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455983/
https://www.ncbi.nlm.nih.gov/pubmed/34584913
http://dx.doi.org/10.1016/j.dib.2021.107352
Descripción
Sumario:Moxifloxacin and levofloxacin are currently recommended as empirical initial treatment options for community-acquired pneumonia (CAP) in China by clinical guidelines and widely used in clinical settings. Several clinical outcomes comparing the efficacy and safety profiles of moxifloxacin versus levofloxacin through a meta-analysis were reported in paper ‘Clinical benefits and cost-effectiveness of moxifloxacin as initial treatment for community-acquired pneumonia: a meta-analysis and economic evaluation’. In this dataset, we aimed at investigating more clinical endpoints comparing the efficacy and safety of moxifloxacin and levofloxacin in the treatment of CAP.

Ejemplares similares